Cedazuridine is a cytidine deaminase inhibitor and uridine analog primarily utilized in combination with decitabine for the treatment of adults diagnosed with myelodysplastic syndromes and chronic myelomonocytic… Read more






Cedazuridine is a cytidine deaminase inhibitor and uridine analog primarily utilized in combination with decitabine for the treatment of adults diagnosed with myelodysplastic syndromes and chronic myelomonocytic leukemia. As a key component of this fixed-dose therapy, maintaining rigorous quality control is essential for ensuring patient safety and treatment efficacy. This category provides access to high-quality Cedazuridine reference standards, including the active pharmaceutical ingredient alongside critical process-related impurities such as epimers, diastereomers, and anomeric forms. Pharmaceutical laboratories and researchers utilize these precise compounds for comprehensive impurity profiling, method validation, and the development of stability-indicating assays. By employing well-characterized reference materials, analytical chemists can reliably identify and quantify degradation products and synthetic by-products, ensuring compliance with regulatory standards throughout the drug development and manufacturing lifecycle.